{"nctId":"NCT01853826","briefTitle":"An Open Label Trial of Afatinib (Giotrif) in Treatment-naive (1st Line) or Chemotherapy Pre-treated Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Harboring EGFR Mutation(s)","startDateStruct":{"date":"2013-07-17","type":"ACTUAL"},"conditions":["Carcinoma, Non-Small-Cell Lung"],"count":481,"armGroups":[{"label":"Afatinib treated-patients","type":"EXPERIMENTAL","interventionNames":["Drug: Afatinib"]}],"interventions":[{"name":"Afatinib","otherNames":["GiotrifÂ®"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion criteria:\n\nPatients with:\n\n* locally advanced or metastatic Non-Small Cell Lung Cancer (NSCLC)\n* Epidermal Growth Factor Receptor (EGFR) mutation-positive result per the institution's testing methodology.\n* Adequate organ function, defined as all of the following:\n\n  1. Absolute Neutrophil Count (ANC) \\> 1500/mm3. (ANC \\>1000/mm3 may be considered in special circumstances such as benign cyclical neutropenia as judged by the investigator and in discussion with the sponsor).\n  2. Platelet count \\>75,000/mm3\n  3. Serum creatinine \\< 1.5 times of the upper limit of normal\n  4. Total Bilirubin \\< 1.5 times upper limit of (institutional) normal (Patients with Gilbert's syndrome total bilirubin must be \\<4 times institutional upper limit of normal).\n  5. Aspartate Amino Transferase (AST) or Alanine Amino Transferase (ALT) \\< three times the upper limit of (institutional) normal (ULN) (if related to liver metastases \\< five times ULN).\n* Eastern Cooperative Oncology Group (ECOG) score between 0 - 2\n* written informed consent by patient or guardian prior to admission into the trial that is consistent with International Conference on Harmonisation (ICH)- Good Clinical Practice (GCP) guidelines and local law.\n\nExclusion criteria:\n\nPatients who or with:\n\n* prior treatment with an EGFR tyrosine kinase inhibitor (TKI)\n* anti-cancer treatment within 2 weeks prior to start of trial treatment (continued use of anti-androgens and/or gonadorelin analogues for treatment of prostate cancer permitted)\n* radiotherapy within 14 days prior to drug administration, except as follows:\n\n  1. Palliative radiation to organs other than chest may be allowed up to 2 weeks prior to drug administration, and\n  2. Single dose palliative treatment for symptomatic metastasis outside above allowance to be discussed with sponsor prior to enrolling.\n* previous or concomitant malignancies at other sites, except effectively treated non-melanoma skin cancers, carcinoma in situ of the cervix, ductal carcinoma in situ or effectively treated malignancy that has been in remission for more than 3 years and is considered to be cured.\n* known pre-existing interstitial lung disease\n* meningeal carcinomatosis and symptomatic brain metastases (patients with asymptomatic brain metastases, who were previously treated, are eligible provided they have had Stable Disease (SD) for at least 4 weeks on stable doses of medication)","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Patients With Adverse Events According to Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0","description":"Number of patients with any treatment emergent adverse event (AE) according to Common Terminology Criteria for Adverse Events (CTCAE) version 3.0.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"478","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":210,"n":479},"commonTop":["Diarrhoea","Rash","Paronychia","Mucosal inflammation","Asthenia"]}}}